# Novo Nordisk Raises 2026 Outlook as Wegovy Pill Sales Reach DKK 5.394B By John Kim Canonical URL: https://www.tokenpost.com/news/business/48875 Published: 2026-11-04T23:47:16.000Z Updated: 2026-11-04T23:47:16.000Z Section: Business > Adjusted sales reached DKK 79.195 billion, up 4% at constant exchange rates. Adjusted operating profit rose 27% at constant exchange rates to DKK 31.72 billion. Novo Nordisk raised its 2026 outlook for sales and operating profit after its Wegovy pill generated DKK 5.394 billion in third-quarter sales across four markets, including the United States. The company now expects adjusted sales and adjusted operating profit to each range from a 2% decline to 2% growth this year at constant exchange rates. Its previous outlook allowed declines of up to 6% or flat results for both measures. The improved outlook reflects higher expectations for GLP-1 product sales. The pill was available in the United States, the United Arab Emirates, the United Kingdom and Germany by quarter-end. Four more launches afterward brought availability to eight markets. Novo Nordisk's adjusted sales totaled DKK 79.195 billion in the quarter, up 4% at constant exchange rates. Adjusted operating profit rose 27% at constant exchange rates to DKK 31.72 billion. Novo Nordisk was listed among companies scheduled to report in an earlier [health care earnings calendar](). ## Links in this article - [health care earnings calendar](https://www.tokenpost.com/news/business/45535)